Abstract: Hemodiafiltration(HDF)works by combining diffusive and convective solute removal to provide a greater removal of larger molecular weight uremic toxins. The recent publication of the CONVINCE study might be a milestone in ending the controversy over whether this treatment modality can provide long-term survival benefits for patients with end-stage renal disease(ESRD)requiring renal replacement therapy. This review gives a brief overview of the current evidence for the clinical benefits of HDF as well as the important factors and stepwise protocols for high-volume HDF achievements.

Key words: Hemodiafiltration, Renal replacement therapy, End-stage renal disease